9. UnitedHealth Group Incorporated (NYSE:UNH)
UnitedHealth Group Incorporated (NYSE: UNH) is technically not a conventional medicine stock. It does not depend on discovering a cancer medicine, receiving an FDA approval or protecting a pharmaceutical patent. Its business is built primarily around health insurance, pharmacy and healthcare services through UnitedHealthcare and Optum. Still, the company belongs in a broader list of the best healthcare stocks because it participates in nearly every major layer of the American healthcare system. It serves patients, employers, physicians, pharmacies, hospitals and government programs, giving it a scale that few healthcare companies can match. That reach can provide steady long-term growth, but it also makes the business operationally complex and more exposed to healthcare regulation than a typical pharmaceutical company.
The company delivered a much stronger second quarter in 2026, reporting $112 billion in consolidated revenue and $8 billion in earnings from operations. Net margin reached 4.9%, while cash flow from operations totaled $11.1 billion. Management also raised its full-year outlook and now expects adjusted net earnings of between $19.50 and $20 per share. UnitedHealthcare served approximately 48.5 million consumers during the quarter, while Optum supported more than 120 million people and generated $65.7 billion in revenue. These figures demonstrate why UnitedHealth Group Incorporated (NYSE: UNH) remains one of the largest and most influential healthcare companies in the world. Even relatively small improvements in margins or medical-cost management can create a meaningful increase in earnings because the revenue base is so enormous.
The limitation is that this is not a pure pharmaceutical growth story. Investors looking for exposure to obesity medicines, oncology breakthroughs, immunology treatments or clinical-trial catalysts will find stronger opportunities elsewhere in the ranking. UnitedHealth Group Incorporated (NYSE: UNH) offers a different proposition: a bet on healthcare utilization, insurance membership, technology-assisted care delivery and the continued expansion of Optum. That model can generate dependable cash flow, but its net margins remain relatively thin, meaning unexpected increases in medical costs can pressure profitability. The stock earns ninth place because its scale and improved 2026 outlook are difficult to ignore, although investors searching specifically for the best medicine stocks to buy and hold may prefer companies that directly own patented therapies and pharmaceutical pipelines.
Click next to see the following stock...
